PHAR (Pharming Group) FFO


PHAR Pharming Group PHAR
79 GF Score
Price $13.09
GF Value $14.23
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group FFO?

FFO (Funds from operations) only applies to REITs.

PHAR
79GF Score
Pharming Group PHAR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.09 is trading 8% below its estimated GF Value™ of $14.23. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • FFO:
  • GF Value™: $14.23 vs. price of $13.09 (8% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score

Get the complete analysis for PHAR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.09
Price
$14.23
GF Value